FDA Warns Bayer on Marketing Practices

The FDA has sent two warning letters to Bayer regarding two aspirins, Bayer Women’s Low Dose Aspirin + Calcium and Bayer Aspirin with Health Advantage. According to the FDA, Bayer’s marketing campaigns make health claims that have not been proven by the federal agency. The Bayer aspirins are marketed as successfully battling osteoporosis and heart disease. The claims have been made with out substantiation or at the very least such substantiation has not been submitted to the FDA.